CJC-1295 No DAC
10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.
$139.99
DetailsHover to zoom
Growth Hormone ResearchSynthetic research compound
CJC-1295 No DAC / Ipamorelin
$59.99
5/5 mgThis preparation supplies modified GRF (1–29) — CJC-1295 without DAC — together with ipamorelin, a selective growth hormone secretagogue receptor agonist.
The pairing gives researchers two distinct receptor inputs to the same pituitary cell population within a single material, which is commonly used when studying convergent signaling on the somatotroph axis in preclinical models.
Research areas
GHRH receptor signalingGhrelin receptor activityCombined-pathway researchPreclinical research
Form: Lyophilized (freeze-dried)
- Compound class
- Synthetic research compound
- Research category
- Growth Hormone Research
- SKU
- NVR-CJC-1295-NO-DAC-IPAMORELIN-5-5MG
- Appearance
- Lyophilized powder
- Storage
- Store lyophilized at −20 °C. Protect from light and moisture.
Research use only
Strength
5/5 mg$59.99$6.00/mg
1
$59.99per 5/5 mg$6.00/mg
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Research Grade
Batch Documentation
Research Use Only
U.S.-Based Fulfillment
What you should know
More detail on CJC-1295 No DAC / Ipamorelin.
Analytical values reflect per-lot documentation and appear once a batch is released.
Compound
The GHRH receptor signals primarily through cyclic AMP while the growth hormone secretagogue receptor signals largely through calcium mobilization, so combining the two agonists lets investigators observe how separate second-messenger systems interact in the same cell. The non-DAC GHRH component keeps the stimulus relatively short, which is useful for time-resolved experiments. Single-agonist controls remain necessary to attribute any observed response. This is a laboratory research material with no established human application.
Peptide class
Synthetic research compound
Mechanism (research context)
Extended mechanistic characterization for this compound is available in the published literature. Consult peer-reviewed references for detailed pathway analysis.
Why it is studied
CJC-1295 No DAC / Ipamorelin is studied within its research category (Growth Hormone Research) as a defined-sequence reference compound for laboratory investigation.
Current areas of research
GHRH receptor signalingGhrelin receptor activityCombined-pathway researchPreclinical research
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
Scientific background
CJC-1295 No DAC / Ipamorelin is supplied for in vitro laboratory research. Batch-specific analytical documentation is provided when available for the released lot.
Related
View all →Related research materials
CJC-1295 w/DAC
5 mg
GHRH analog with Drug Affinity Complex modification for extended-duration receptor research.
$79.99
DetailsGHRP-2 Acetate
10 mg
Second-generation growth hormone releasing peptide studied as a ghrelin receptor agonist reference.
$39.99
DetailsGHRP-6 Acetate
10 mg
Early growth hormone releasing hexapeptide widely cited as a ghrelin receptor research standard.
$39.99
DetailsCJC-1295 No DAC / Ipamorelin
5/5 mg · $59.99